We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+12.73%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$180M
AUM Growth
+$46.4M
Cap. Flow
+$32.9M
Cap. Flow %
18.26%
Top 10 Hldgs %
72.12%
Holding
23
New
5
Increased
9
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$13.1M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.72M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$6.96M
4
ATXS
Astria Therapeutics
ATXS
+$6.19M
5
CYTK icon
Cytokinetics
CYTK
+$4.56M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$4.92M
2
CBAY
Cymabay Therapeutics
CBAY
+$4.11M
3
SAGE
Sage Therapeutics
SAGE
+$3.7M
4
FOLD
Amicus Therapeutics
FOLD
+$2.86M
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$20.2M 11.18%
524,811
+17,993
+4% +$462K
CRNX icon
2
Crinetics Pharmaceuticals
CRNX
$8.88B
$16.9M 9.38%
938,677
+197,634
+27% +$3.94M
COGT icon
3
Cogent Biosciences
COGT
$6.68B
$13.5M 7.51%
+1,143,368
New +$13.1M
CYTK icon
4
Cytokinetics
CYTK
$10.9B
$13.3M 7.35%
406,225
+123,339
+44% +$4.56M
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
$13M 7.21%
1,187,801
-441,663
-27% -$4.11M
KALV
6
DELISTED
KalVista Pharmaceuticals
KALV
$12.7M 7.05%
1,412,336
+290,354
+26% +$2.68M
BIIB icon
7
Biogen
BIIB
$30.4B
$11.7M 6.48%
41,047
+3,588
+10% +$1.07M
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$10.2M 5.68%
99,495
+278
+0.3% +$29.3K
APLS
9
DELISTED
Apellis Pharmaceuticals
APLS
$9.78M 5.43%
107,406
-15,759
-13% -$1.36M
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$8.73M 4.84%
152,360
-94,256
-38% -$4.92M
ITOS
11
DELISTED
iTeos Therapeutics
ITOS
$8.42M 4.67%
636,158
+155,505
+32% +$2.22M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.5B
$8.03M 4.45%
+92,626
New +$8.72M
ASND icon
13
Ascendis Pharma A/S
ASND
$17.1B
$7M 3.88%
78,442
+1,232
+2% +$107K
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$2.36B
$6.72M 3.73%
954,856
-208,679
-18% -$1.67M
SRPT icon
15
Sarepta Therapeutics
SRPT
$1.82B
$6.18M 3.43%
+53,995
New +$6.96M
ATXS
16
DELISTED
Astria Therapeutics
ATXS
$5.31M 2.95%
637,857
+536,518
+529% +$6.19M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$2.02B
$3.64M 2.02%
+173,717
New +$3.62M
SAGE
18
DELISTED
Sage Therapeutics
SAGE
$3.32M 1.84%
70,559
-74,459
-51% -$3.7M
ARGX icon
19
argenx
ARGX
$53.8B
$1.59M 0.88%
+4,081
New +$1.61M
SCLX icon
20
Scilex Holding
SCLX
$59.4M
$57.9K 0.03%
297
– –
ARQT icon
21
Arcutis Biotherapeutics
ARQT
$3.56B
– –
-178,217
Closed -$1.96M
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
– –
-258,288
Closed -$2.86M
TSVT
23
DELISTED
2seventy bio
TSVT
– –
-172,188
Closed -$1.76M

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
FWM
FFT Wealth Management Philadelphia, Pennsylvania $552M AUM 16.82% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return

Saturn V Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Saturn V Capital Management held 23 positions worth $180M, up 35% from $134M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Saturn V Capital Management deployed $32.9M of net new capital in Q2 2023, opening 5 new positions and adding to 9 existing holdings. Its largest new stake was Cogent Biosciences: 1,143,368 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $4.92M trimmed.

  • Saturn V Capital Management's largest Q2 2023 buy was Cogent Biosciences: 1,143,368 shares worth $13.5M.
  • Saturn V Capital Management added most to Astria Therapeutics in Q2 2023, an estimated $6.19M increase.
  • Saturn V Capital Management's biggest Q2 2023 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $4.92M.
  • Saturn V Capital Management fully exited Amicus Therapeutics in Q2 2023, selling an estimated $2.86M.
  • Saturn V Capital Management's ten largest holdings make up 72% of its $180M portfolio in Q2 2023.
  • Saturn V Capital Management opened 5 new positions and closed 3 in Q2 2023.
  • Saturn V Capital Management's portfolio value rose 35% quarter-over-quarter to $180M.

Based on Saturn V Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.